TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome
Brief Summary: Currently Morphine and or Methadone are the most commonly used drugs in the treatment for NAS along with supportive care. Many care providers offer tolerance "low lactose" formula to these infants to alleviate gastrointestinal symptoms. There are no clinical studies to support this practice and it is currently unknown that low lactose formula really helps or not in management of NAS.

This is a Randomized Double Blind Clinical Trial to assess the role of low lactose formula versus standard (regular) formula in managing NAS.


Options:
A: Arm Label: SVS vs Control; Type: EXPERIMENTAL; Interventions: Device: Stochastic Vibrotactile Stimulation (SVS), Other: Control | Intervention Type: DEVICE; Name: Stochastic Vibrotactile Stimulation (SVS); Assigned to Arm(s): SVS vs Control | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): SVS vs Control
B: Arm Label: Music Therapy; Type: EXPERIMENTAL; Interventions: Other: Music Therapy | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Music Therapy; Assigned to Arm(s): Music Therapy
C: Arm Label: Low lactose formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Arm Label: Regular formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Low lactose or regular formula | Intervention Type: OTHER; Name: Low lactose or regular formula; Assigned to Arm(s): Low lactose formula, Regular formula
D: Arm Label: Buprenorphine; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: Methadone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): Buprenorphine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Physical Therapy Interventions Directed at the Low Back Versus Low Back and Hips for Individuals With a Primary Complaint of Low Back Pain: A Randomized Clinical Trial
Brief Summary: Low back pain (LBP) is the leading cause of disability worldwide and has substantial impacts on pain and function for an individual. Some individuals with LBP seek physical therapy for their condition. The purpose of the study is to determine whether individuals with LBP have improved pain and disability following physical therapy targeting either the low back only or low back plus hip(s).


Options:
A: Arm Label: S-A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stay-active care | Arm Label: S-A+stretch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stay-active care+stretching | Arm Label: S-A+stretch+manther; Type: EXPERIMENTAL; Interventions: Procedure: Stay-active+stretching+manual therapy | Arm Label: S-A+stretch+manther+sterinject; Type: EXPERIMENTAL; Interventions: Procedure: Stay-active+stretching+manual therapy+steroid injections | Intervention Type: PROCEDURE; Name: Stay-active care; Assigned to Arm(s): S-A | Intervention Type: PROCEDURE; Name: Stay-active care+stretching; Assigned to Arm(s): S-A+stretch | Intervention Type: PROCEDURE; Name: Stay-active+stretching+manual therapy; Assigned to Arm(s): S-A+stretch+manther | Intervention Type: PROCEDURE; Name: Stay-active+stretching+manual therapy+steroid injections; Assigned to Arm(s): S-A+stretch+manther+sterinject
B: Arm Label: Low Back Only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Low Back Only | Arm Label: Low Back+Hip; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Low Back+Hip | Intervention Type: PROCEDURE; Name: Low Back Only; Assigned to Arm(s): Low Back Only | Intervention Type: PROCEDURE; Name: Low Back+Hip; Assigned to Arm(s): Low Back+Hip
C: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Early Physical Therapy with Usual Care; Type: EXPERIMENTAL; Interventions: Other: Early Physical Therapy with Usual Care, Other: Usual Care | Intervention Type: OTHER; Name: Early Physical Therapy with Usual Care; Assigned to Arm(s): Early Physical Therapy with Usual Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Early Physical Therapy with Usual Care, Usual Care
D: Arm Label: Usual Care (UC); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual Care (UC) | Arm Label: Early Physical Therapy (PT); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Early Physical Therapy (PT) | Intervention Type: PROCEDURE; Name: Usual Care (UC); Assigned to Arm(s): Usual Care (UC) | Intervention Type: PROCEDURE; Name: Early Physical Therapy (PT); Assigned to Arm(s): Early Physical Therapy (PT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Mixed Methods Investigation of Brief Mindfulness Training and Self-injury Attentional Bias Among Self-injuring Adolescents
Brief Summary: My study will employ a convergent mixed methods two-arm parallel randomized controlled design. The qualitative strand will primarily rely on semi-structured interview procedures to answer the following questions: (1) How do adolescents perceive and experience the phenomenon of nonsuicidal self-injury (NSSI)? (2) What do adolescents believe needs to be done to address NSSI? The quantitative strand will primarily rely on clinical interview data, self-report measures, and an experimental task protocol to answer the following question: What is the impact of a brief mindfulness induction (versus a control condition) on self-injury attentional bias among self-injuring adolescents?


Options:
A: Arm Label: Mindfulness condition; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness | Arm Label: Control condition; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mindfulness; Assigned to Arm(s): Mindfulness condition
B: Arm Label: Dialectical behavior therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Arm Label: alternative psychotherapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Dialectical behavior therapy (DBT) | Intervention Type: BEHAVIORAL; Name: Dialectical behavior therapy (DBT); Assigned to Arm(s): Dialectical behavior therapy, alternative psychotherapy
C: Arm Label: Cognitive Analytic Informed Brief Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive analytic informed brief therapy | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive analytic informed brief therapy; Assigned to Arm(s): Cognitive Analytic Informed Brief Therapy
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: APSOM vs Control | Arm Label: APSOM; Type: OTHER; Interventions: Other: APSOM vs Control | Intervention Type: OTHER; Name: APSOM vs Control; Assigned to Arm(s): APSOM, Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Activation for Dementia Caregivers: Scheduling Pleasant Events and Enhancing Communications
Brief Summary: This project was designed to test a model targeted intervention for dementia caregivers telephone program consisting of both psychoeducation and behavioral activation components to reduce the burden of caregivers. The program is delivered by telephone to increase accessibility and sustainability for caregivers.


Options:
A: Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral activation, Other: Psychoeducation | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Other: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Behavioral activation; Assigned to Arm(s): Behavioral Activation | Intervention Type: OTHER; Name: Psychoeducation; Assigned to Arm(s): Behavioral Activation, Psychoeducation
B: Arm Label: Psycho-educational program; Type: EXPERIMENTAL; Interventions: Behavioral: psycho-social intervention based on a web-based psycho-educational program, called Diapason. | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Consultation in memory clinic | Intervention Type: BEHAVIORAL; Name: psycho-social intervention based on a web-based psycho-educational program, called Diapason.; Assigned to Arm(s): Psycho-educational program | Intervention Type: BEHAVIORAL; Name: Consultation in memory clinic; Assigned to Arm(s): Standard treatment
C: Arm Label: intervention; Type: EXPERIMENTAL; Interventions: Other: structured support groups | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: structured support groups; Assigned to Arm(s): intervention
D: Arm Label: Behavioral Skills Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Skills Training: Experimental | Arm Label: Basic Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Education | Intervention Type: BEHAVIORAL; Name: Basic Education; Assigned to Arm(s): Basic Education | Intervention Type: BEHAVIORAL; Name: Behavioral Skills Training: Experimental; Assigned to Arm(s): Behavioral Skills Training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behavioral Activation for Dementia Caregivers: Scheduling Pleasant Events and Enhancing Communications
Brief Summary: This project was designed to test a model targeted intervention for dementia caregivers telephone program consisting of both psychoeducation and behavioral activation components to reduce the burden of caregivers. The program is delivered by telephone to increase accessibility and sustainability for caregivers.


Options:
A: Arm Label: Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral activation, Other: Psychoeducation | Arm Label: Psychoeducation; Type: ACTIVE_COMPARATOR; Interventions: Other: Psychoeducation | Intervention Type: BEHAVIORAL; Name: Behavioral activation; Assigned to Arm(s): Behavioral Activation | Intervention Type: OTHER; Name: Psychoeducation; Assigned to Arm(s): Behavioral Activation, Psychoeducation
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: My Tools 4 Care | Arm Label: Educational Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: My Tools 4 Care; Assigned to Arm(s): Intervention
C: Arm Label: Immediately Receive Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Immediately Receive Tool | Arm Label: One Month Delay; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: One Month Delay | Intervention Type: BEHAVIORAL; Name: Immediately Receive Tool; Assigned to Arm(s): Immediately Receive Tool | Intervention Type: BEHAVIORAL; Name: One Month Delay; Assigned to Arm(s): One Month Delay
D: Arm Label: iSupport for dementia - European-Portuguese version; Type: EXPERIMENTAL; Interventions: Behavioral: iSupport for dementia - European-Portuguese version | Arm Label: Education-only e-book; Type: ACTIVE_COMPARATOR; Interventions: Other: e-book (comparator) | Intervention Type: BEHAVIORAL; Name: iSupport for dementia - European-Portuguese version; Assigned to Arm(s): iSupport for dementia - European-Portuguese version | Intervention Type: OTHER; Name: e-book (comparator); Assigned to Arm(s): Education-only e-book

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Alirocumab for Thin-cap fIbroatheroma in Patients With Coronary Artery Disease Estimated by Optical Coherence Tomography: Single Center, Randomized, Open-label, Trial
Brief Summary: the purpose of this study is to show that alirocumab with statin therapy have a s tronger stabilizing effect on vulnerable plaque in coronary artery disease than statin alone administration


Options:
A: Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Biological: Evolocumab, Other: Standard of care | Arm Label: Evolocumab + SOC; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab + SOC, Standard of Care | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of Care
B: Arm Label: Alirocumab therapy group; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab | Arm Label: standard statin therapy group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab therapy group
C: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Atorvastatin, Drug: Ezetimibe, Other: Diet Only | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Evolocumab, Placebo | Intervention Type: OTHER; Name: Diet Only; Assigned to Arm(s): Evolocumab, Placebo
D: Arm Label: Alirocumab 75 /up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for ezetimibe), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Ezetimibe 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Ezetimibe, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg | Intervention Type: DRUG; Name: Placebo (for ezetimibe); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 /up to 150 mg Q2W, Ezetimibe 10 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
Brief Summary: This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of placebo and experience disease recurrence may be eligible to switch over to pembrolizumab 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \~2 years) in Part 2 in an open label design. The primary hypothesis of this study is that pembrolizumab increases recurrence-free survival (RFS) compared to placebo.

Per protocol, response/ progression or adverse events (AEs) during re-challenge/switch-over in Part 2 will not be counted towards the RFS outcome measure or safety outcome measures respectively.


Options:
A: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Pembrolizumab, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Nivolumab and CMP-001 Combination; Type: EXPERIMENTAL; Interventions: Drug: CMP-001, Biological: Nivolumab | Intervention Type: DRUG; Name: CMP-001; Assigned to Arm(s): Nivolumab and CMP-001 Combination | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab and CMP-001 Combination
C: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab | Arm Label: D; Type: EXPERIMENTAL; Interventions: Drug: Domatinostat, Drug: Nivolumab, Drug: Ipilimumab | Intervention Type: DRUG; Name: Domatinostat; Assigned to Arm(s): B, C, D | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): A, B, C, D | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine for the Treatment of Social Deficits in Youth with Disorders of Impaired Social Interactions: a Randomized-controlled Trial
Brief Summary: This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

This study consists of up to 6 visits to Massachusetts General Hospital.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine for the Treatment of Social Deficits in Youth with Disorders of Impaired Social Interactions: a Randomized-controlled Trial
Brief Summary: This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

This study consists of up to 6 visits to Massachusetts General Hospital.


Options:
A: Arm Label: Arm 1: 12 weeks of study drug then 15 weeks of placebo; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 15 weeks of placebo then 12 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL, Drug: Placebo | Arm Label: Arm 3: 27 weeks of study drug; Type: EXPERIMENTAL; Interventions: Drug: Oral cannabidiol 100mg/mL | Intervention Type: DRUG; Name: Oral cannabidiol 100mg/mL; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug, Arm 3: 27 weeks of study drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 1: 12 weeks of study drug then 15 weeks of placebo, Arm 3: 15 weeks of placebo then 12 weeks of study drug
B: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
D: Arm Label: Transdermal nicotine first, placebo last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Arm Label: Transdermal placebo first, nicotine last; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine, Other: Transdermal placebo | Intervention Type: DRUG; Name: Transdermal nicotine; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last | Intervention Type: OTHER; Name: Transdermal placebo; Assigned to Arm(s): Transdermal nicotine first, placebo last, Transdermal placebo first, nicotine last

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Memantine for the Treatment of Social Deficits in Youth with Disorders of Impaired Social Interactions: a Randomized-controlled Trial
Brief Summary: This study is a 12-week randomized-controlled trial of memantine hydrochloride (Namenda) for the treatment of social impairment in youth with Non-Verbal Learning Disorder, High-Functioning Autism Spectrum Disorder, and related conditions. Eligible participants will be males and females ages 8-18.

This study consists of up to 6 visits to Massachusetts General Hospital.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
D: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B